Skip to main content


Details of the Drug
Generic Name:
Drug Type:
Bispecific GPRC5D-directed CD3 T-cell engager
How the Drug is Given:

Injection, for subcutaneous use 


Indications and Usage

Talquetamab-tgvs is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Side effects needing medical attention

The most common adverse reactions are fever, Cytokine Release Syndrome, dysgeusia (altered taste in mouth), nail disorder, musculoskeletal pain, skin disorder, rash, fatigue, weight decreased, dry mouth, dry skin, dysphagia (swallowing difficulties), upper respiratory tract infection, diarrhea, hypotension, and headache. The most common laboratory abnormalities are lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, and hemoglobin decreased.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.